Absci Corporation ABSI Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| R&D by Product | ||||||
| Drug creation program and platform | $6.08M+52.4% | $5.4M+10.6% | $5.67M+36.8% | $5.29M+37.0% | $3.99M+10.0% | |
| External preclinical and clinical development | $4.29M+59.7% | $10.74M+158% | $3.61M+26.4% | $5.37M+134% | $2.68M+9,841% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Absci Corporation break its business down?
- Absci Corporation (ABSI) reports r&d by product across 2 parts — Drug creation program and platform and External preclinical and clinical development. Each is extracted from the segment footnotes and tracked over time.
- Where does Absci Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Absci Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
